NICE ‘no’ for Opdivo/Yervoy lung cancer combo
The combination is not considered to be a cost-effective use of NHS resources in this setting
Read More
Tag: ipilimumab
FDA, EMA accept Opdivo-Yervoy filings in lung cancer
The filing is based on data from the CheckMate-9LA trial, which showed a benefit in overall survival
Read More
BMS’ Opdivo disappoints in late-stage trial
However, a clear trend was demonstrated towards improvement in overall survival.
Read More
Promising early results for BMS’ investigational HCC study
The company are “encouraged by these early results”, as liver cancer affects over 5,700 new patients in the UK each year.
Read More
NICE turns down Opdivo/Yervoy combo for kidney cancer
The National Institute for Health and Care Excellence has published draft guidelines rejecting NHS funds for Opdivo/Yervoy for untreated metastatic renal cell carcinoma.
Read More
BMS files Opdivo/Yervoy combo for lung cancer
US regulators have accepted Bristol-Myers Squibb’s application to market its immunotherapy Opdivo plus Yervoy for the treatment of first-line advanced non-small cell lung cancer (NSCLC) in certain patients.
Read More
BMS’ Opdivo/Yervoy combo cleared for kidney cancer
US regulators have approved a combination of Bristol-Myers Squibb’s immunotherapy drugs Opdivo and Yervoy as a first-line treatment for patients with advanced renal cell carcinoma.
Read More
Opdivo/Yervoy combo beats chemo on PFS in lung cancer
Bristol-Myers Squibb has revealed that a combination of its immunotherapies Opdivo and Yervoy was superior to chemo alone in keeping disease progression at bay in patients with non-small cell lung cancer (NSCLC).
Read More
Mixed results for BMS’ Opdivo, Yervoy combo in kidney cancer
A combination of Bristol-Myers Squibb’s Opdivo and Yervoy has failed to significantly improve progression-free survival (PFS) compared to Pfizer’s Sutent in patients with renal cancer.
Read More
BMS, Novartis to test Mekinist/Opdivo combo
Novartis and Bristol-Myers Squibb have signed a clinical research pact to investigate the safety, tolerability, and efficacy of combining their respective drugs Mekinist and Opdivo.
Read More
- Liverpool and McMaster University announce £300,000 strategic research partnership
- Study finds link between malaria parasites developing antimalarial drug resistance
- Researchers develop ‘digital twin’ heart models to better monitor PAH NHS patients
- Closed Loop and Pharmanovia investigate precision medicine combination in hypertension
- US study reveals interferon combinations cause lupus symptoms and affect treatment
